{
    "root": "b6585925-c3fb-4b61-808d-42ea232ca899",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Optison",
        "suffix": {
            "text": "Perflutren Protein-Type A Microspheres"
        }
    },
    "value": "20250514",
    "ingredients": [
        {
            "name": "N-ACETYL-DL-TRYPTOPHAN",
            "code": "4460NBV53F"
        },
        {
            "name": "CAPRYLIC ACID",
            "code": "OBL58JN025"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "HUMAN ALBUMIN MICROSPHERES",
            "code": "T8C6W1N6NW"
        },
        {
            "name": "PERFLUTREN",
            "code": "CK0N3WH0SR"
        }
    ],
    "indications": "optison indicated adult pediatric patients suboptimal echocardiograms opacify left ventricle improve delineation left ventricular endocardial borders .",
    "contraindications": "adults 0.5 ml intravenously rate exceeding 1 ml/s . contrast enhancement inadequate dose 0.5 ml , additional doses 0.5 ml may repeated total 5 ml 10-minute period maximum total dose 8.7 ml one patient study ( 2.1 ) . pediatric patients 28 kg less : 0.2 ml diluted 0.2 ml 0.9 % sodium chloride injection . 29 kg 40 kg : 0.3 ml diluted 0.3 ml 0.9 % sodium chloride injection . 41 kg : 0.4 ml diluted 0.4 ml 0.9 % sodium chloride injection . administer intravenously rate exceeding 0.05 ml/s . contrast enhancement inadequate initial dose , four additional doses diluted volume may repeated contrast enhancement needed ( 2.1 ) . follow optison injection flush 0.9 % sodium chloride injection 5 % dextrose injection ( 2.3 ) . full prescribing information preparation instructions ( 2.2 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "optison contraindicated patients known suspected hypersensitivity perflutren albumin [ ( 5.2 ) ] .",
    "indications_original": "OPTISON is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.",
    "contraindications_original": "Adults 0.5 mL intravenously at a rate not exceeding 1 mL/s. If contrast enhancement is inadequate after the dose of 0.5 mL, additional doses of 0.5 mL may be repeated up to a total of 5 mL in a 10-minute period with a maximum total dose of 8.7 mL in any one patient study ( 2.1 ). Pediatric Patients 28 kg or less: 0.2 mL diluted with 0.2 mL of 0.9% Sodium Chloride Injection. 29 kg to 40 kg: 0.3 mL diluted with 0.3 mL of 0.9% Sodium Chloride Injection. 41 kg or more: 0.4 mL diluted with 0.4 mL of 0.9% Sodium Chloride Injection. Administer intravenously at a rate not exceeding 0.05 mL/s. If contrast enhancement is inadequate after the initial dose, up to four additional doses of the same diluted volume may be repeated for further contrast enhancement as needed ( 2.1 ). Follow the OPTISON injection with a flush of 0.9% Sodium Chloride Injection or 5% Dextrose Injection ( 2.3 ). See full prescribing information for preparation instructions ( 2.2 ).",
    "adverseReactions_original": "OPTISON is contraindicated in patients with known or suspected hypersensitivity to perflutren or albumin [see Warnings and Precautions (5.2)]."
}